NOV 0 1 2004 30 H

Under the Progress Reduction Act of 1995. TRANSMITTAL FORM (to be used for all correspondence after initial in	Filing Date First Named Inventor Art Unit Examiner Name	Approved for use through 07/31/2006. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it displays a valid OMB control number. 10/743,613 December 22, 2003 Paul Spurr 1614
Total Number of Pages in This Submission	Attorney Docket Number	21436
	ENCLOSURES (Check all that a	anniv)
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks Cited Reference Search Report	Other Enclosure(s) (please Identify below):
Firm		
or Individual name Kimberly J. Price	or $\left(\begin{array}{c} 1 \\ 1 \end{array} \right)$	
Signature Date 10/29/04	ely Fres	
10/29/04	-	
CI	ERTIFICATE OF TRANSMISSION/	MAILING
I hereby certify that this correspondence is b	peing facsimile transmitted to the USPTO or d	leposited with the United States Postal Service with

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Kimberly J. Prior) ^		
Signature	Venberl	Ath	(S)	Date	10/29/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Paul Spurr et al Group: 1614

Serial No. 10/743,613, filed December 22, 2003 Examiner:

Docket No. 21436 US

For: CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE

DERIVATIVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 Date October 29, 2004

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the document listed on enclosed Form PTO-1449.

Document B18 listed on Form PTO-1449 is enclosed.

Enclosed is a Search Report, dated October 1, 2004, issued by the European Patent Office in PCT/EP 03/14928 application corresponding to the captioned application. The Search Report lists Documents B3 and C18. Document B3 is not being submitted because it has been made of record in an Information Disclosure Statement sent to the USPTO March 22, 2004.

Consideration of the document cited on Form PTO-1449 is requested.

Serial No. 10/743,613

Filed: December 22, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application and/or because each item of information contained in the Information Disclosure Statement was cited in a communication for the first time from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Kimberly J. Prior (Reg. No. 41,483)

340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6208

Telefax: (973) 235-2363

146809

Complete if Known Substitute for add/1449A/PTO
INFORMATION DISCLOSURE Application Number 10/743,613 STATEMENT BY APPLICANT Filing Date December 22, 2003 First Name Inventor Paul Spurr (Use several sheets if necessary) Group Art Unit 1614 Examiner Name Attorney Docket Number 21436 US of 1 Sheet

NON PATENT LITERATURE DOCUMENTS

Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	T ²
INO."	issue number(s), publisher, city and/or country where published	
C18		
	Transactions 1, XP002296456, pgs. 1363-1368 (1999)	
		<u> </u>
_		
		-
		ļ
		ļ
	DATE	
	CONSIDERED	
	No.1	No.¹ of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. C18 CARLA BOGA et al, Journal of the Chemical Society, Perkin Transactions 1, XP002296456, pgs. 1363-1368 (1999)

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *Applicant is to place a check mark here if English language Translation or abstract is attached.

146808